High expression of bcl-xL in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis

Acta Haematologica

Volumn 113, Issue 4, 2005, Pages 247-254

  Zhang, Jing ^a   Wang, Ji Cun ^a   Han, Yue Heng ^a   Wang, Ii Feng ^a   Ji, Shao Ping ^a   Liu, Shan Xi ^b   Liu, Xin Ping ^a   Yao, Li Bo ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antisense; K562 cells; NB4 cells bcl xL; Realgar; RNA

Indexed keywords

ARSENIC DERIVATIVE; COMPLEMENTARY RNA; PROTEIN BCL XL; REALGAR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL SPECIFICITY; CELL STRAIN K 562; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA VECTOR;

APOPTOSIS; ARSENICALS; BASE SEQUENCE; BCL-X PROTEIN; DNA PRIMERS; HUMANS; K562 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFIDES;

EID: 21344469428     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084678     Document Type: Article

References (29)

1. Zhang C, Huang S, Xiang Y: Study on the lower doses of realgar that induced NB4 cell apoptosis. Chin J Bas Med TCM 2000;6:11-13.
2. Wang MC, Li XM, Liu SX: A clinical study of realgar on ATRA-resistant acute promyelocytic leukemia and its effects on apoptosis induction. J Xi'an Med Univ 2002;23:175-177.
3. Hao HY, Teng ZP, Lu DP: Apoptotic effect of tetra-arsenic tetra-sulfide on acute promyelocytic leukemia cell line NB4. Chin J Pharmacol Toxicol 2002;16:37-40.
4. Soignet SL, Maslak P, Wang ZG: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-1348.
5. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
6. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-2111.
7. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
8. Damiano JS, Hazlehurst LA, Dalton WS: Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001;15:1232-1239.
9. Sattler M, Salgia R: Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 1997;8:63-79.
10. L. J Exp Med 2000;191:977-984.
11. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
12. Guo XZ: Poisonous Herbal Medicine Dictionary. Tianjin, Technical Translation Press, 1992, vol 3, pp 552-556.
13. Zhu J, Okumura H, Ohtake S, Nakamura S, Nakao S: The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol 2003;110:1-10.
14. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S: Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: A role of Bcl-2. Mol Cancer Ther 2003;2:711-719.
15. Au WY, Kumana CR, Kou M, Mak R, Chan GC, Lam CW, Kwong YL: Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003;102:407-408.
16. Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93:268-277.
17. Bai Y, Huang S: Studies on red orpiment induction of NB4 and HL-60 cell apoptosis. Chin J Hematol 1998;19:477-480.
18. Zhu Q, Chen G, Huang Y: The relationship between sensitivity to arsenic trioxide and antioxidative capacity of malignant hematopoietic cells. Chin J Oncol 2000;22:359-361.
19. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860.
20. Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X: The inherent cellular level of reactive oxygen species: One of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis 2002;7:209-215.
21. Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T: Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003;101:4990-4997.
22. Zhang T, Wang SS, Hong L, Wang XL, Qi QH: Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo. J Exp Clin Cancer Res 2003;22:61-68.
23. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC: Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 2002;277:44988-44995.
24. 3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 2001;193:1361-1371.
25. Watson RW, Redmond HP, Wang JH, Bouchier-Hayes D: Mechanism involved in sodium arsenite-induced apoptosis of human neutrophils. J Leukoc Biol 1996;60:625-632.
26. Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G: Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999;249:413-421.
27. Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, Almasan A, Tang H, Chen Q: Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 2004;23:1239-1247.
28. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G: Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000;19:307-314.
29. Ferrao PT, Frost MJ, Siah SP, Ashman LK: Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003;102:4499-4503.